Pharmaceutical

Biogen and Neomorph enter molecular glue degrader deal

Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare conditions.

Nov 1, 2024 - 04:00
Biogen and Neomorph enter molecular glue degrader deal
Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare conditions.
Read the original article

Tags:

Previous Article

Bladder cancer diagnoses to top 300,000 in major markets by 2033

Next Article

Will the tide turn for the wave of pharma layoffs?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

DEA will delay telemedicine restrictions for buprenorphine, Adderall, and other drugs

DEA will delay telemedicine restrictions for buprenorph...

May 3, 2023

Darovasertib by Ideaya Biosciences for Colorectal Cancer: Likelihood of Approval

Darovasertib by Ideaya Biosciences for Colorectal Cance...

Nov 2, 2023

BIO-Europe 2023: Barriers remain in the AI pharma revolution

BIO-Europe 2023: Barriers remain in the AI pharma revol...

Nov 12, 2023